BSE · 540686
Smruthi Organics Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹102 Cr with net profit ₹3 Cr — a 3.36% net margin, versus 2.83% the period before.
Shareholding
As of 2026-06-30
- Promoter64.73%
- Public35.27%
5,959 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.73× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #17 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,06,654 Cr | 274.97 | 12.31 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹27,068 Cr | 205.48 | 16.37 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹25,271 Cr | 118.83 | 13.5 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,568 Cr | 129.46 | 2.18 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,753 Cr | 67.98 | 2.42 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,715 Cr | 110.8 | 4.72 | 12.98% | 11.5% |
| Hikal Limited | ₹2,730 Cr | 189.21 | 2.28 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,264 Cr | 250.08 | 9.25 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,009 Cr | 148.95 | 6.1 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,329 Cr | 67.82 | 3.27 | 17.67% | 13.66% |
| Smruthi Organics Limited(this company) | ₹135 Cr | 36.07 | 1.82 | 4.66% | 3.36% |
AI analysis
AI-generated · google/gemini-2.5-flashSmruthi Organics Limited has a market capitalization of Rs 132 Cr. The company's revenue for the most recent period was Rs 126.1 Cr, with a profit margin of 336.4%. Its debt-to-equity ratio is 0.2. The promoter holding stands at 64.7275%.
Positives
- +The debt-to-equity ratio is low at 0.2.
- +The company reported a high profit margin of 336.4%.
- +Promoter holding is substantial at 64.7275% as of June 30, 2026, with no shares pledged.
Negatives
- −The company's revenue decreased to Rs 126.0967 Cr in March 2025 from Rs 127.7186 Cr in March 2024.
- −Net profit declined to Rs 3.5629 Cr in March 2025 from Rs 3.5903 Cr in March 2024.
- −EPS has shown a declining trend over the last three years, falling from Rs 9.07 in Mar 2022 to Rs 3.11 in Mar 2025.
- −The company reported negative net profit of Rs -1.1 Cr in June 2025.
- −Revenue decreased from Rs 38.09 Cr in March 2025 to Rs 29.09 Cr in March 2026 for the respective quarters.
Financial performance
Smruthi Organics Limited reported revenue of Rs 126.0967 Cr in March 2025, a decrease from Rs 127.7186 Cr in March 2024. Net profit also declined to Rs 3.5629 Cr in March 2025 from Rs 3.5903 Cr in March 2024. The company's highest annual revenue in the past five years was Rs 141.1483 Cr in March 2023.
Profitability & returns
The company’s profit margin was 336.4%. Return on capital employed (ROCE) was 7.7464%. Earnings per share (EPS) for March 2025 was Rs 3.11, a slight decrease from Rs 3.14 in March 2024. The return on equity (ROE) is stated as 466%.
Balance sheet
Smruthi Organics Limited maintains a debt-to-equity ratio of 0.2. The book value per share is Rs 64.23. No information regarding other specific balance sheet items is provided in the available data.
Ownership & pledges
As of June 30, 2026, promoter shareholding in Smruthi Organics Limited was 64.7275%, while public shareholding was 35.2725%. There was no reported FII or DII holding. The number of shareholders as of June 30, 2026, was 5959. There are no promoter pledges reported.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.